Submit a Manuscript to the Journal

Journal of Dermatological Treatment

For an Article Collection on

JAK Inhibitors in Alopecia Areata: A Comprehensive Review, Pearls, and Conundrums

Manuscript deadline
05 April 2024

Cover image - Journal of Dermatological Treatment

Article collection guest advisor(s)

Steven Feldman, Wake Forest University
[email protected]

Peter van de Kerkhof, Radboud University
[email protected]

Submit an ArticleVisit JournalArticles

JAK Inhibitors in Alopecia Areata: A Comprehensive Review, Pearls, and Conundrums

Alopecia areata (AA) is an autoimmune, genetic disease that causes relapsing and remitting nonscarring hair loss, affecting up to 2% of the global population. AA is a condition where the psychological burden has been less widely recognized. Patients with AA have reported lower health-related quality of life scores compared to patients with other skin conditions, including psoriasis or atopic dermatitis. Until recently, there were no FDA-approved therapies for AA, using an assortment of topical, intralesional, and systemic agents as the central management strategy. Cytokines have critical roles in the pathogenesis of immunological and inflammatory diseases and can be targeted therapeutically. Targeted, small-molecule therapies that inhibit Janus kinase (JAK) proteins (essential signaling mediators that act downstream of pro-inflammatory cytokines) have gained traction as efficacious options for treating inflammatory disorders, including alopecia areata.

With the introduction of the first US Food and Drug Administration (FDA)–approved medication for alopecia areata (AA)—the Janus kinase (JAK) inhibitor, baricitinib—there is an essential focus on this disease in the literature.

Learning the use of JAK inhibitors in children, dealing with refractory patients, adverse drug reactions, and planning a maintenance dose in successful cases are some everyday problems dermatologists may encounter. A comprehensive review of the different JAK inhibitors addressing those conundrums will help practicing dermatologists.

For any queries regarding this Article Collection, please contact Autumn Zellers at [email protected].

Benefits of publishing open access within Taylor & Francis

Global marketing and publicity, ensuring your research reaches the people you want it to.

Article Collections bring together the latest research on hot topics from influential researchers across the globe.

Rigorous peer review for every open access article.

Rapid online publication allowing you to share your work quickly.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.